Clinical effects of MIR-101 on prognosis of hepatocellular carcinoma and carcinogenic mechanism of anti-MIR-101

Abstract

The aim of this study was to verify whether anti-miR-101 participates in the treatment of hepatocellular carcinoma (HCC) as a small-molecule antitumor agent, and to explore the effect on phosphatase and tensin homolog deleted on chromosome 10 (PTEN). Patients who received consecutive hepatectomies were followed-up, and MIR-101 expressions in their tumor and paracancerous tissues were detected. Correlation between MIR-101 expression and clinical pathological factors and prognosis was studied. High-throughput sequencing was used to detect the genetic and microRNA (miRNA) levels of tumor tissues. Expression of anti-miR-101 in different HCC cell lines was determined, and those of desired genes and proteins were detected by qRT-PCR and western blotting to obtain the target gene. MIR-101 was significantly upregulated in HCC patients compared with that in paracancerous tissues. High MIR-101 expression, vascular invasion, tumor size =7 cm and late pathological stage were the risk factors of recurrence-free survival rate. High MIR-101 expression was the independent prognostic factor of total and recurrence-free survival rates. CXCL12, IL6R, FOXO3 and PTEN were screened as desired genes, and only PTEN was expressed significantly differently in three cell lines. MIR-101 could bind 3'-UTR of WT-PTEN with reduced fluorescent intensity, suggesting that PTEN was the target gene. SMMC-7721, HepG2 and Huh7 were eligible cell lines for MIR-101 studies. MIR-101 was an applicable molecular marker of HCC. Anti-miR-101 regulated the transcription of PTEN and may promote cell proliferation, differentiation and apoptosis by regulating downstream genes with PTEN. The regulatory effects of anti-miR-101 on PTEN provide valuable evidence for finding novel miRNA drugs.